Compare Eli Lilly And Co (LLY) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Value Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,141 (market cap $1.02T), while Vanguard Value Index Fund ETF trades at $217.45. The key difference: Eli Lilly And Co pays a 0.6% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals.
| LLY | VTV | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $220.51 |
52-Week Low | $625.65 | $175.51 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
VTV trades at $216.94, down 0.45% on the day, with a neutral technical signal and bullish moving averages. Recent news highlights its role as a stability-focused ETF amid AI sector volatility, with a 16% year-to-date gain. The fund's low expense ratio and value-oriented portfolio attract investors rotating away from tech.
The outlook for VTV hinges on continued value stock outperformance and Federal Reserve policy. Risks include inflation sensitivity and tech sector rebounds. Analyst sentiment is balanced, with the ETF positioned for defensive growth but vulnerable to macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
